TLR5 and neoplasm: Ex vivo biodistribution studies were performed to validate the imaging results and to further quantify the 125I‐antiTLR5 mAb uptake at 24, 48 and 72 hours in the TLR5+/− 4T1 tumour‐bearing model group (Figure 4A).